Table 2.

Differences in patients with and without F3/F4

Variable	No F3/F4 during first two years (N=368)	F3/F4 during first two year (N=101)	P-value
Recipient Race (% Black)	19.0%	34.7%	0.002
Donor Race (% Black)	19.3%	12.9%	0.1
Recipient/Donor Race Combination	69.0% W/W (N=254) 12.0% W/B (N=44) 7.3% B/B (N=27) 11.7% B/W (N=43)	59.4% W/W (N=60) 5.9% W/B (N=6) 6.9% B/B (N=7) 27.7% B/W (N=28)	0.001
Recipient Gender (% Female)	24.2%	35.6%	0.02
Donor Gender (% Female)	62.5%	66.3%	NS
CMV High Risk (D+/R−)	16.3%	21.8%	0.2
Combined Kidney transplant	6.0%	8.9%	NS
Living Related transplant	5.7%	5.9%	NS
Donation after cardiac death	2.7%	2.2%	NS
HBV Surface Antigen Positive	2.1%	2.1%	NS
Recipient Diabetes	24.0%	16.0%	0.1
Hepatocellular Carcinoma	21.0%	17.2%	NS
Alcohol Cirrhosis Comorbidity	45.0%	41.7%	NS
Treated for acute rejection	22.6%	37.6%	0.002
Treated for HCV recurrence	32.3%	38.6%	0.2
Recipient Albumin	2.9 ± 0.6	2.8 ± 0.7	NS
Recipient INR	1.6 ± 0.9	1.7 ± 0.9	NS
Recipient Creatinine	1.6 ± 1.5	1.6 ± 1.6	NS
Recipient Pre-transplant Log Viral Load	5.5 ± 1.0 (N=133)	5.8 ± 0.9 (N=43)	0.1
Anti-Lymphocyte Induction	37.5%	39.2%	NS
Recipient Age	52.7 ± 7.4	50.7 ± 8.1	0.02
Donor Age	38.3 ± 15.7	41.4 ± 14.8	0.07
Recipient BMI	29.5 ± 14.1	29.7 ± 17.8	NS
Cold Ischemia Time (In Hours)	6.8 ± 2.4	7.0 ± 5.0	NS

BMI: body mass index; HCV: Hepatitis C Virus; LT: Liver Transplantation; B/W: Black/White; D+/R−: Donor positive, recipient negative; NS: Non-significant; F3/F4: Fibrosis stage 3 or 4